Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3P5DA)

Drug Name
Rofecoxib Drug Info
Synonyms
Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
5090
ChEBI ID
CHEMBL122
CAS Number
CAS 162011-90-7
TTD Drug ID
D05VLS
VARIDT Drug ID
DR00753
INTEDE Drug ID
DR1433

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Complement and coagulation cascades 2.24 0.00e+0 76/85 (89.41%) CFH;C1QA;SERPINA5;...
DNA replication 2.19 0.00e+0 34/36 (94.44%) MCM2;PCNA;PRIM1;...
Spliceosome 2.06 3.37e-3 101/150 (67.33%) SNRPD1;SRSF1;HNRNPA1;...
Valine, leucine and isoleucine degradation 2.00 2.53e-3 42/48 (87.5%) HMGCS2;ACADSB;EHHADH;...
Cell cycle 1.88 5.06e-3 110/124 (88.71%) CDC25B;E2F2;MCM2;...
Mismatch repair 1.81 9.27e-3 22/23 (95.65%) MSH6;MLH3;PCNA;...
Peroxisome 1.68 4.48e-2 72/82 (87.8%) PEX11A;SLC27A2;EHHADH;...
Pyrimidine metabolism 1.67 4.36e-2 40/56 (71.43%) TYMS;DPYD;DPYS;...
Ribosome biogenesis in eukaryotes 1.62 4.80e-2 52/108 (48.15%) NVL;REXO5;NAT10;...
IL-17 signaling pathway -1.70 2.38e-2 84/94 (89.36%) MAPK7;ANAPC5;IFNG;...
Hepatitis B -1.71 2.31e-2 151/162 (93.21%) ARAF;TNF;STAT5A;...
Oxytocin signaling pathway -1.72 2.07e-2 128/154 (83.12%) EGFR;EEF2;ITPR1;...
Glutamatergic synapse -1.73 1.88e-2 97/114 (85.09%) GRK3;PPP3CC;GNG3;...
Yersinia infection -1.74 1.66e-2 120/137 (87.59%) ITGA4;ROCK2;PLCG1;...
Natural killer cell mediated cytotoxicity -1.75 1.61e-2 99/131 (75.57%) CD244;GZMB;HLA-A;...
Human cytomegalovirus infection -1.75 1.55e-2 201/225 (89.33%) TRAF5;IFNA17;PRKACG;...
Inflammatory mediator regulation of TRP channels -1.76 1.62e-2 82/98 (83.67%) MAPK14;NGF;ADCY3;...
Aldosterone-regulated sodium reabsorption -1.76 1.35e-2 34/37 (91.89%) KRAS;ATP1B2;NEDD4L;...
Choline metabolism in cancer -1.76 1.42e-2 84/98 (85.71%) CHKB;RALGDS;SLC44A4;...
Circadian entrainment -1.77 1.41e-2 85/97 (87.63%) RYR2;GNG3;GNG11;...
Viral myocarditis -1.77 1.33e-2 53/60 (88.33%) HLA-A;CXADR;CASP8;...
Gap junction -1.79 1.16e-2 72/88 (81.82%) MAP3K2;SOS1;SOS2;...
Influenza A -1.80 1.14e-2 156/172 (90.7%) BAK1;PRSS3;TICAM1;...
Intestinal immune network for IgA production -1.81 1.12e-2 38/48 (79.17%) HLA-DRB1;LTBR;CD40;...
Endocrine and other factor-regulated calcium reabsorpti... -1.82 9.93e-3 49/53 (92.45%) DNM1;CLTA;KLK1;...
Th1 and Th2 cell differentiation -1.85 8.51e-3 80/92 (86.96%) IL2RB;PLCG1;PPP3CC;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.85 9.17e-3 79/89 (88.76%) MAPK13;MAP2K6;NFKBIA;...
Salivary secretion -1.85 9.93e-3 76/93 (81.72%) ATP1A2;ADRB3;KCNN4;...
Aldosterone synthesis and secretion -1.86 9.48e-3 85/98 (86.73%) PDE2A;ADCY3;ADCY7;...
Mitophagy -1.90 5.96e-3 56/68 (82.35%) MFN1;FIS1;ULK1;...
Amoebiasis -1.91 3.31e-3 99/102 (97.06%) IFNG;ACTN1;CD1D;...
Morphine addiction -1.92 3.72e-3 80/91 (87.91%) KCNJ5;GABRG2;GABRA2;...
GnRH signaling pathway -1.94 2.13e-3 80/93 (86.02%) MMP2;MAP3K2;SOS1;...
Malaria -1.96 2.48e-3 44/50 (88%) CD40;TGFB3;CR1;...
Graft-versus-host disease -1.96 2.98e-3 32/42 (76.19%) CD80;HLA-G;HLA-DRA;...
GABAergic synapse -1.99 3.72e-3 76/89 (85.39%) GNG3;GNG11;SLC38A2;...
Lysosome -2.02 0.00e+0 115/128 (89.84%) ATP6V0A2;GGA1;NAGPA;...
Rheumatoid arthritis -2.19 0.00e+0 78/93 (83.87%) TGFB3;ATP6V0B;ANGPT1;...
Insulin secretion -2.28 0.00e+0 75/86 (87.21%) ADCY3;ADCY7;CCKAR;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H